摘要
目的:探讨含铂类化疗药物联合恩度治疗晚期非小细胞肺癌的临床疗效及安全性。方法:收集和纳入2013年11月至2015年4月晚期非小细胞肺癌患者78例,将其按就诊编号顺序分为观察组(39例)与对照组(39例)。对照组患者以含铂类化疗药物进行化疗;观察组患者以含铂类化疗药物联合恩度为治疗方案,对比疗效和不良反应。结果:观察组疗效明显高于对照组(P<0.05)。观察组不良反应与对照组差异无统计学意义(P>0.05)。结论:含铂类化疗药物联合恩度治疗晚期非小细胞肺癌的临床疗效显著优于单纯以含铂类化疗药物进行化疗者,且不增加毒副作用,安全性高。
Objective:To explore clinical efficacy and safety of platinum chemotherapy drugs combined with Endostar in treatment of advanced non-small cell lung cancer.Methods:78patients with advanced non-small cell lung cancer had been collected from November 2013 to June 2015 and divided into the observation group(39cases)and the conventional group(39cases).The patients in the conventional group had been treated with platinum chemotherapy drugs,the patients in the observation group with platinum chemotherapy drugs combined with Endostar.The efficacy and adverse reactions had been compared.Results:The curative effect of the observation group was significantly higher than that of the conventional group(P<0.05).The adverse reactions in both groups were similar(P>0.05).Conclusion:The efficacy of platinum chemotherapy drugs combined with Endostar is significantly better than the drugs only in treatment of advanced non-small cell lung cancer with less side effects,and higher safety,which can be applied widely in clinic.
关键词
含铂类化疗药物
恩度
非小细胞肺癌
晚期
临床疗效
安全性
platinum chemotherapy drugs
endostar
advanced non-small cell lung cancer
clinical efficacy
safety
